Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.58 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.